Where are we with the benefit-risk ratio of JAK inhibitors in rheumatoid arthritis?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Where are we with the benefit-risk ratio of JAK inhibitors in rheumatoid arthritis?

Published:2022-11 Issue:6 Volume:89 Page:105454
ISSN:1297-319X
Container-title:Joint Bone Spine
language:en
Short-container-title:Joint Bone Spine

Author:

Avouac Jérôme

Publisher

Elsevier BV

Subject

Rheumatology

Reference18 articles.

1. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis;Ytterberg;N Engl J Med,2022

2. Comparison of major cardiovascular and thromboembolic events in safety reports between rheumatoid arthritis patients treated with JAK inhibitors versus anti-TNF: results from VigiBase;Montastruc;Ann Rheum Dis,2022

3. Risk of major cardiovascular event across jak inhibitor treated patients: analysis of a national claim database;Gouverneur;Ann Rheum Dis,2021

4. The relationship between weight status and metabolic syndrome in patients with rheumatoid arthritis and spondyloarthritis;Giraud;Joint Bone Spine,2021

5. Dietary recommendations of the French Society for Rheumatology for patients with chronic inflammatory rheumatic diseases;Daien;Joint Bone Spine,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DAS28-γGT for the prediction of major cardiovascular events in rheumatoid arthritis: results from the ESPOIR cohort;Rheumatology;2023-05-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP